Pneuma Respiratory


Founded in 2015, Pneuma Respiratory is focused on creating therapeutic treatments for diseases of the lungs using a digital first platform for inhaled drug delivery.  Our focus is to improve the potential effectiveness of currently available and novel drugs, with the initial targets being approved therapeutics for asthma and COPD.  Pneuma is leveraging more than three decades of healthcare research and product development experience along with hand held device design and manufacturing expertise. 

Pneuma’s team includes former executives from Abbott Labs, Bayer, GE Healthcare, Merck, Pfizer, Boehringer Ingelheim and Foxconn.  Our medical advisors are thought leaders at Harvard, the Cleveland Clinic, Johns Hopkins, and the Mayo Clinic.


Company Leadership


Steven Kesten, MD, FCCP, serves as Pneuma’s President and Chief Medical Officer. Prior to joining Pneuma, Dr. Kesten, a pulmonary physician, served in senior management positions in the pharmaceutical and medical device industries, including Vice President of Marketed Respiratory Products and prior to that, as Director of Clinical and Regulatory affairs for Boehringer Ingelheim Pharmaceuticals’ respiratory group. Dr. Kesten had a critical role in the clinical development, global regulatory approvals and commercialization of Spiriva®. He had leadership responsibilities for other respiratory products at Boehringer Ingelheim including Combivent® and other product lines in the Respimat® device. Dr. Kesten has also been a Vice-President and Chief Medical Officer at both medical device and cell therapy companies.

Eric Hunter serves as the Company’s Chief Executive Officer. Mr. Hunter is author or co- author on over 130 patents. He has extensive experience in the founding and managing a range of businesses in the high technology, manufacturing and medical device industries. Two of these companies, Cree Inc. and Charles & Colvard LLC, are publicly traded on Nasdaq. Mr.

Hunter also co-founded a medical device company, Quill Medical, which was sold to Angiotech Pharmaceuticals, Inc. for $200 million in 2005 and an eye care company, Corinthian Ophthalmic, Inc., that was sold to Eyenovia, Inc. in 2014.

Rich Gimigliano serves as Pneuma's Chief Financial Officer and is a senior financial executive with outstanding analytical skills, proven leadership and a record of building successful businesses. He has extensive investment banking experience across equity, debt and advisory assignments. His experience includes positions as managing director at Viant Capital, managing director investment banking at Merriman Capital, partner at ThinkEquity LLC and at Thomas Weisel Partners, and a managing director at Montgomery Securities, Lehman Brothers and Credit Suisse First Boston.

Jack Hebrank, PhD serves as Pneuma’s Chief Scientific Officer. With a PhD in Mechanical and Electrical Engineering from Duke University, Dr. Hebrank taught fluid mechanics for 18 years at North Carolina State University. He also has had an impressive career as Director of Technical Development for Embrex from 1997-2007. After Embrex was acquired by Pfizer, Dr. Hebrank served as Senior Principal Scientist for Pfizer from 2007-2015.

Jacky Li serves as Director of High Volume Manufacturing Team. Mr. Li has an impressive manufacturing career working as a Senior Manager at Foxconn and brings to Pneuma 20+ years of high volume manufacturing experience in world-leading products.

Huey Wang serves as Pneuma’s General Manager for Asia. Mr. Wang has an MBA from UC Berkeley and a MSEE in Electrical and Computer Engineering from the University of Wisconsin. Prior to joining Pneuma, he was Senior Director of Technical Marketing at Macronix, Director of IP Portfolio Marketing at TSMC, and Corporate Venture Fund Manager at Mosel Vitelic.

J. Sid Clements, PhD serves as Pneuma’s Droplet Physics Advisor and is a world expert in aerosolized droplet physics and electrostatistics. A former Fulbright Fellowship recipient, Dr. Clements was a Faculty Fellow in NASA’s electrostatics and advanced materials laboratory. Dr. Clements is a Professor (Physics Department) at Appalachian State University, a consultant for Boeing, and Exxon Fellow in the IEEE.


Board of Directors 

Walt Robb, PhD, the former Senior VP of General Electric, serves as the Chairman of the Board and is a liaison to the medical device industry. In his career at GE, Dr. Robb led GE Medical (now GE Healthcare) for 13 years and GE Corporate R&D for 6 years. He grew GE Medical from 1,000 to 10,000 employees. Dr. Robb received the National Medal of Technology from President Clinton for his leadership in the CT and MR imaging industry.

Jay Morgan, the former Chief Operating Officer for Research Operations at Merck Consumer Health, serves as a Director. At Merck, he led global product development and founded a Human Centered Design team as Vice President of Innovation. Further, Mr. Morgan has also led innovation for Bayer Consumer Health as VP Global Innovation & Design. As a founding member of the non-profit Memphis Innovation Bootcamp, Mr. Morgan is committed to helping equip community leaders, businesses and educators realize a better future through innovation best practices.

Douglas Stoner, Special Council for Hoffman Warnick LLC, a leading Boston-based intellectual property law office, serves as a Director. Much of Mr. Stoner’s practice is devoted to licensing matters and cooperative research agreements directed toward maximizing the impact of IP on profits. Prior to joining Hoffman Warnick LLC, he enjoyed a 28-year career with General Electric where he served as chief IP Counsel at GE Medical Systems for 14 years and as General Counsel at GE Corporate Research and Development for 9 years. Mr. Stoner directed GE’s IP departments in the US, France, Japan and India